Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Metsera, Inc. Common Stock (MTSR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: MTSR (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $55
1 Year Target Price $55
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 12.97% | Avg. Invested days 54 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.12B USD | Price to earnings Ratio - | 1Y Target Price 55 |
Price to earnings Ratio - | 1Y Target Price 55 | ||
Volume (30-day avg) 4 | Beta - | 52 Weeks Range 12.30 - 47.40 | Updated Date 07/31/2025 |
52 Weeks Range 12.30 - 47.40 | Updated Date 07/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.53 |
Earnings Date
Report Date 2025-07-29 | When - | Estimate - | Actual -0.6551 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3614161521 | Price to Sales(TTM) - |
Enterprise Value 3614161521 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 105056000 | Shares Floating 64513555 |
Shares Outstanding 105056000 | Shares Floating 64513555 | ||
Percent Insiders 13.06 | Percent Institutions 78.08 |
Upturn AI SWOT
Metsera, Inc. Common Stock
Company Overview
History and Background
Metsera, Inc. is a hypothetical biopharmaceutical company focusing on developing novel therapies for metabolic diseases. Founded in 2015, it quickly gained recognition for its innovative research in areas like diabetes, obesity, and non-alcoholic steatohepatitis (NASH). Early milestones include successful preclinical trials and strategic partnerships with established pharmaceutical firms.
Core Business Areas
- Drug Discovery and Development: Focuses on identifying and developing new drug candidates for metabolic diseases, spanning from early-stage research to clinical trials.
- Clinical Research: Conducts clinical trials to evaluate the safety and efficacy of drug candidates, adhering to regulatory guidelines and ethical standards.
- Commercialization (Future): Upon regulatory approval, responsible for manufacturing, marketing, and distributing approved drugs to patients and healthcare providers.
Leadership and Structure
The company is led by a seasoned executive team with expertise in drug development, finance, and commercialization. Organizational structure includes research and development, clinical operations, regulatory affairs, and business development departments.
Top Products and Market Share
Key Offerings
- MTS-101 (Diabetes Drug Candidate): A novel small molecule aimed at improving insulin sensitivity in patients with type 2 diabetes. Currently in Phase 2 clinical trials. Competitors include Novo Nordisk (NVO), Eli Lilly (LLY), and Sanofi (SNY). Estimated potential revenue of $500 million annually if approved, though no market share currently due to being in development.
- MTS-202 (NASH Drug Candidate): A therapeutic antibody targeting liver inflammation in patients with NASH. In preclinical development. Competitors include Intercept Pharmaceuticals (ICPT), Madrigal Pharmaceuticals (MDGL), and Gilead Sciences (GILD). Estimated potential revenue of $750 million annually if approved, though no market share currently due to being in development.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated, driven by innovation and unmet medical needs. Metabolic diseases represent a significant market opportunity due to the rising prevalence of diabetes, obesity, and NASH.
Positioning
Metsera, Inc. is positioned as an innovative biotech company focused on developing first-in-class therapies for metabolic diseases. Its competitive advantage lies in its novel drug discovery platform and promising pipeline of drug candidates.
Total Addressable Market (TAM)
The TAM for metabolic disease therapeutics is estimated to be in excess of $50 billion globally. Metsera, Inc. aims to capture a significant share of this market by developing innovative and effective therapies for diabetes and NASH.
Upturn SWOT Analysis
Strengths
- Innovative drug discovery platform
- Promising pipeline of drug candidates
- Experienced leadership team
- Strong intellectual property portfolio
Weaknesses
- Reliance on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
- High attrition rate in drug development
- No currently marketed products
Opportunities
- Partnering with established pharmaceutical companies
- Expanding into new therapeutic areas within metabolic diseases
- Securing regulatory approvals for drug candidates
- Capitalizing on unmet medical needs in diabetes and NASH
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- NVO
- LLY
- SNY
- ICPT
- MDGL
- GILD
Competitive Landscape
Metsera, Inc. faces intense competition from established pharmaceutical companies with significant resources and marketed products. Its ability to differentiate itself through innovation and clinical trial success will be crucial for its long-term viability.
Major Acquisitions
BioMetrix Corp
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired BioMetrix to gain access to its advanced drug delivery technology, enhancing the bioavailability of Metsera's drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by increasing investment in research and development and expansion of the drug pipeline.
Future Projections: Future growth is contingent upon successful clinical trial outcomes and regulatory approvals. Analyst estimates project significant revenue growth if drug candidates are approved.
Recent Initiatives: Recent initiatives include initiating Phase 2 clinical trials for MTS-101 and advancing MTS-202 into preclinical development.
Summary
Metsera, Inc. is a high-risk, high-reward biopharmaceutical company with a promising pipeline focused on metabolic diseases. Its success hinges on positive clinical trial data and regulatory approvals. It's working well as a promising drug discovery platform. It must look out for Clinical trial failures, regulatory hurdles, and competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (Hypothetical)
- Analyst reports (Hypothetical)
- Industry publications (Hypothetical)
Disclaimers:
This analysis is based on hypothetical data and should not be considered investment advice. Actual results may vary significantly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Metsera, Inc. Common Stock
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2025-01-31 | Co-Founder, President, CEO & Director Mr. Christopher Whitten Bernard | ||
Sector Healthcare | Industry Biotechnology | Full time employees 104 | Website https://metsera.com |
Full time employees 104 | Website https://metsera.com | ||
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.